NCT05894707

Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers

A Randomized, Double-blinded, Dose-escalation Phase Ia Study to Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Sinocelltech Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The goal of clinical trial is to evaluate the safety and tolerability of SCT650C in healthy participants.

Detailed description

Interleukin-17A (IL-17A) is a new potential therapeutic target which plays important role in pathogenesis of several autoimmune disorders including psoriasis, rheumatoid arthritis, possibly - systemic lupus erythematosus (SLE) and multiple sclerosis (MS). SCT650C is a novel humanized monoclonal antibody against human IL-17A developed by Sinocelltech which is now on the first step of clinical evaluation. SCT650C-612-1-01 study is the first-in-human clinical trial which is intended to evaluate tolerability, safety, pharmacokinetics and immunogenicity of SCT650C in healthy volunteers.

Conditions

• Autoimmune Disease

Interventions

Type	Name	Description
DRUG	SCT650C	Recombinant anti-IL-17A antibody

Timeline

• Start date: 2023-06-01
• Primary completion: 2023-11-01
• Completion: 2024-03-01
• First posted: 2023-06-08
• Last updated: 2023-06-08

Locations

3 sites across 1 country: Australia